CytoCorp Changes Its Name to CytoCore.CHICAGO -- CytoCorp, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). : MCDG.OB) announced today that it is changing its name to CytoCore, Inc. The Company's Board approved the name change during the recent January Board meeting. The Company will be "doing business as" CytoCore, Inc. until the name is officially ratified rat·i·fy tr.v. rat·i·fied, rat·i·fy·ing, rat·i·fies To approve and give formal sanction to; confirm. See Synonyms at approve. by a vote of the shareholders at the annual shareholders meeting in 2006. CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. David Weissberg stated: "We wanted to change the Company name for an important reason. There are many exciting developments that we have been working on over the past several months, and based on the expanded products and markets which we will be addressing with multiple press releases over the next several weeks, we believe that this name better represents our larger prospects." The Company will continue to operate with the same stock symbol, MCDG.OB, until the Shareholders meeting at which time a new symbol will be acquired. About CytoCore, Inc. CytoCore develops cost-effective bio-molecular cancer screening systems, which can be utilized in a laboratory or at the point-of-care, to assist in the early detection of cervical, uterine uterine /uter·ine/ (u´ter-in) pertaining to the uterus. u·ter·ine adj. Of, relating to, or in the region of the uterus. , gastrointestinal, and other cancers. The InPath(TM) System is being developed to provide medical practitioners with a highly accurate, low-cost, cervical cancer Cervical Cancer Definition Cervical cancer is a disease in which the cells of the cervix become abnormal and start to grow uncontrollably, forming tumors. screening system that can be integrated into existing medical models or at the point-of-care. More information is available at: www.Molecular-Dx.com Certain statements in this release are forward-looking. These statements are based on CytoCore's current expectations and involve many risks and uncertainties, such as the company's inability to obtain sufficient financing, the possibility that clinical trials will not substantiate To establish the existence or truth of a particular fact through the use of competent evidence; to verify. For example, an Eyewitness might be called by a party to a lawsuit to substantiate that party's testimony. CytoCore's expectations with respect to the InPath(TM) System, and other factors set forth in reports and documents filed by Molecular Diagnostics with the Securities and Exchange Commission. Actual results may differ materially from CytoCore's current expectations depending upon a number of factors affecting the Company's business. These factors include, among others, risks and uncertainties detailed in the Company's periodic public filings with the Securities and Exchange Commission, including but not limited to the Company's Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended December 31, 2004 and its Quarterly Reports on Form 10-QSB for the quarters ended March 31, 2005 and June 30, 2005. Except as expressly required by law, CytoCore undertakes no obligation to publicly update or revise any forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. contained herein. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion